



Mission Therapeutics (Cambridge, UK) has announced the appointment of **Paul Wallace** (left) as chief business officer. Wallace has worked in business development roles within drug discovery companies for nearly 20 years. He joins the company from Medivir, where he most recently was executive vice president and head of business development.

“With Mission currently embarking on the preclinical development of its lead molecules, Paul’s extensive business development experience will be invaluable in helping us find the right strategic partnerships to fully realize the potential of these assets,” says CEO Anker Lundemose. “Our core focus is cancer, but our platform discovery approach has yielded highly promising molecules for other indications, such as Parkinson’s disease. We see partnering as an attractive option for taking these non-core projects forward.”

post as CEO after 17 years at Millennium. Mersana also announced a \$35 million round of Series B financing as it plans to file for permission to bring two drugs to clinical trials.

**Richard Scheller** has been appointed CSO and head of therapeutic development of 23andMe (Mountain View, CA, USA). Scheller retired from Genentech in December 2014 after serving as CSO and, after the company’s acquisition, as executive vice president of Roche’s Genentech Research and Early Development (gRED) business unit. 23andMe announced in March that in addition to selling consumer genetic tests and data to its pharma partners, it plans to mine its genomic database for potential drug targets.

Kamada (Ness Ziona, Israel) has announced the appointment of **Eran Schenker** to the newly created position of vice president–medical director. He joins Kamada from Neurim Pharmaceuticals, where he served as medical director, business development manager and, later, as vice president.

**Daniel Soland** has been named to the board of directors of DBV Technologies (Bagneux, France). He was most recently senior vice president and COO of ViroPharma and currently serves on the board of Tarsa Therapeutics.

**James Tursi** has been named chief medical officer of Innocoll (Athlone, Ireland). He was most recently vice president of R&D and chief medical officer at Auxilium. Previously, he was responsible for medical affairs for cervical cancer vaccines in North America for GlaxoSmithKline.

Chamaeleo Pharma (Diegem, Belgium) has announced that **Han Van ‘t Klooster** has joined the company as vice president of commercial operations. He previously served as general manager of Pharmion Europe (acquired by Celgene) and international marketing director, oncology at Chiron (acquired by Novartis).

**Christopher Viehbacher** has joined the board of directors of venture creation firm PureTech (Boston). Viehbacher was formerly CEO and board member of Sanofi, and chairman of the board of Genzyme. PureTech recently closed a \$107 million funding round.

Agbiotech company Inocucor Technologies (Montreal) has announced the appointment of **Ted Crosbie** to its board of directors. Crosbie was most recently vice president of integrated farming systems and director of global wheat breeding at Monsanto until his retirement in 2014. He currently serves as chief technology officer and chair of the Iowa Innovation Council for the state of Iowa.

Actavis (Dublin) has named two former members of the Allergan board of directors to its own board: **Michael R. Gallagher**, who served as lead independent director and chair of the organization and compensation committee, and **Peter J. McDonnell**, who served on the corporate governance and compliance committee and the science and technology committee. In November 2014, Actavis agreed to buy Allergan for a combination of cash and stock valued at \$66 billion.

Kymab (Cambridge, UK) has appointed **Anne Hyland** as CFO. Hyland was most recently serving as CFO of BBI Diagnostics Group and Vectura Group. She is a nonexecutive director and chair of the audit committee of Elementis.

Cortendo (Goteborg, Sweden, and Radnor, PA, USA) has announced the appointments of **John H. Johnson** as chairman of the board of directors and **Richard Kollender** as a director. Johnson currently serves on the boards of directors of Cemptra Pharmaceuticals, Histogenics, Portola Pharmaceuticals and Sucampo Pharmaceuticals and previously served as chairman of Dendreon and Tranzyme Pharma. Kollender is chairman of Rapid Micro

Biosystems and serves as a director for Celator Pharmaceuticals and Tarsa Therapeutics.

Chiasma (Newton, MA, USA), which recently raised \$70 million in Series E financing, has named **Mark Leuchtenberger** as president and CEO, succeeding **Roni Mamluk**, who will become the company’s chief development officer. Leuchtenberger previously served as CEO of Acusphere, Rib-X Pharmaceuticals, Targanta Therapeutics and Therion Biologics. From 1996 to 2002, he oversaw commercial operations at Biogen Idec, including the launch of its blockbuster drug Avonex (interferon  $\beta$ -1a).

InMed Pharmaceuticals (Vancouver, British Columbia, Canada) has appointed former associate medical director of GW Pharmaceuticals **Abo Mohammed** as chief medical officer.

Agbiotech company Arcadia Biosciences (Davis, CA, USA) has named **Thomas P. O’Neil** CFO. He has more than 20 years of finance and operations experience in private and large public companies. Most recently, he served as CFO of Sorbent Therapeutics.

**Matthew L. Posard** has joined molecular diagnostics developer Trovagene (San Diego) as executive vice president and chief commercial officer. He was previously senior vice president and general manager of new and emerging market opportunities at Illumina.

Oncology startup Mersana Therapeutics (Cambridge, MA, USA) has appointed **Anna Protopoulos**, formerly head of Millennium Pharmaceuticals, as CEO. Protopoulos left her